Please assess the completion status of the following clinical trial:

Trial Title: Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed germ cell tumor (GCT), including 1 of the following primary tumor sites:~  * Seminoma~    * Testis~   * Retroperitoneum~   * Mediastinum~   * Other extragonadal site~ * Nonseminoma~    * Testis~   * Retroperitoneum~   * Other extragonadal site~      * No tumor of the mediastinum~* Must have evidence of metastatic disease, including either of the following:~  * Unidimensionally measurable lesions~    * At least 20 mm by conventional techniques (e.g., physical exam for clinically palpable lymph nodes and superficial skin lesions or chest x-ray for clearly defined lung lesions surrounded by aerated lung) OR at least 10 mm by spiral CT scan or MRI~ * Nonmeasurable lesions, including the following:~    * Small lesions~   * Bone lesions~   * Pleural or pericardial effusions~   * Ascites~   * Irradiated lesions, unless progression is documented after radiotherapy~* Progressive or recurrent disease meeting at least 1 of the following criteria:~  * Measurable progressive disease~ * Biopsy-proven residual disease~ * Persistently elevated or rising ß-human chorionic gonadotropin (HCG) or alpha-fetoprotein (AFP) titers with no other clear cause for elevation~* Previously treated with 1 and only 1 regimen comprising etoposide and cisplatin with or without bleomycin AND exhibits clinical resistance by at least 1 of the following conditions after therapy\*:~  * Progressive GCT after a partial response to first-line therapy~ * Relapse after complete response (CR) to first-line therapy, including partial response (PR) surgically converted to CR~ * Second testicular primary with evidence of metastases after first-line therapy~ * Relapse after adjuvant chemotherapy NOTE: \*Patients failing to achieve PR or CR with first-line therapy as evidenced by rising markers or new disease within 4 weeks of first-line therapy are not eligible~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Granulocyte count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9 g/dL (transfusion allowed)~Hepatic~* Bilirubin ≤ 1.5 times upper limit of normal\* (ULN)~* AST and ALT ≤ 2.5 times ULN\* NOTE: \*Unless hepatic metastases are present~Renal~* Creatinine ≤ 1.5 times ULN OR~* Creatinine clearance ≥ 50 mL/min~Other~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior dose-intensive therapy with stem cell replacement~Chemotherapy~* See Disease Characteristics~* At least 3 weeks since prior chemotherapy~* No prior paclitaxel~* No prior docetaxel~* No prior ifosfamide~* No other concurrent chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~* At least 3 weeks since prior radiotherapy~* Concurrent or sequential radiotherapy to brain metastases allowed~* No other concurrent palliative radiotherapy~Surgery~* See Disease Characteristics~* Concurrent surgery for brain metastases allowed~Other~* Recovered from prior therapy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Regimen A: TIP (Type: EXPERIMENTAL): None
- Regimen B: VeIP (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).